Neoadjuvant Treatment for Advanced Rectal Carcinoma

Inclusion Criteria: * Patient ≥75 years * Eastern Cooperative Oncology Group (ECOG) ≤2 * Adenocarcinoma of the rectum histologically proven * Tumor ≤12 cm from the anal margin, the measurement done by rigid rectoscopy or by sub peritoneal MRI * Require a pre-operative treatment (tumor classified T3 or T4 resectable by MRI and tomodensitometry or T2 of the very low rectum) * Patient operable * No radiologically detectable metastases * Absolute Neutrophile count (ANC) ≥1500/mm³; Platelets ≥100 000/mm³ and Hemoglobin ≥10 g/dL * Bilirubin ≤1.5 x upper limit of normal (ULN), aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) ≤1.5 x upper limit of normal (ULN), Alkaline Phosphatase ≤1.5 x upper limit of normal (ULN) * Creatinine clearance ≥30 ml/min (Cockcroft and Gault) * Uracilemia \< 16ng/mL * Public or private Health Insurance coverage * Patient has been informed and signed the informed consent document Exclusion Criteria: * Non-resectable tumor * History of chronic diarrhea or an inflammatory disease of the colon or rectum, or intestinal obstruction or sub-obstruction * History of pelvic radiotherapy * Any active febrile infection or any other serious underlying pathology that may prevent the patient from receiving the treatment * Significant Cardiovascular diseases such as, but not limited to: cardiovascular or myocardial infarction ≤6 months before inclusion, congestive heart failure class II or higher (NYHA), unstable angina, arrhythmia requiring medic…